Table 5.
Multivariate Cox-regression analysis for predicting TTR and OS in 293 HCC patients with Microvascular Invasion with and without adjuvant Lenvatinib before PSM.
| Variable | Multivariable Analysis (TTR) | Multivariable Analysis (OS) | ||||
|---|---|---|---|---|---|---|
| HR | 95%CI | P | HR | 95%CI | P | |
|
HBV-DNA, IU/mL >2000 vs. ≤2000 |
– | – | – | 1.56 | 1.06-2.29 | 0.023 |
|
AFP, ng/mL >400 vs. ≤400 |
1.50 | 1.05-2.15 | 0.025 | 1.56 | 1.05-2.33 | 0.028 |
|
Tumor number
Multiple vs. Single |
1.83 | 1.19-2.81 | 0.006 | 2.07 | 1.31-3.25 | 0.002 |
|
Microvascular invasion
M2 vs. M1 |
2.22 | 1.54-3.22 | <0.001 | 2.37 | 1.59-3.55 | <0.001 |
|
Margin
Wide vs. Narrow |
0.50 | 0.35-0.71 | <0.001 | 0.47 | 0.32-0.69 | <0.001 |
|
Lenvatinib
Yes vs. No |
0.44 | 0.27-0.72 | 0.001 | 0.42 | 0.24-0.73 | 0.002 |
Bold values indicate statistical significance (P < 0.05). OS, overall survival; TTR, time to recurrence; HCC, Hepatocellular Carcinoma; PSM, propensity score matching. HBV-DNA, hepatitis B virus-deoxyribonucleic acid; AFP, alpha fetoprotein.